PRO-DEX, INC. Proceeds from Long-Term Debt Issued
PRO-DEX, INC. (PDEX) reported Proceeds from Long-Term Debt Issued of $12.89 million for the 9-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2025-05-01
- PRO-DEX, INC. proceeds from issuance of long-term debt for the quarter ending 2025-03-31 was $4.40M.
- PRO-DEX, INC. proceeds from issuance of long-term debt for the quarter ending 2024-12-31 was $3.50M.
- PRO-DEX, INC. proceeds from issuance of long-term debt for the quarter ending 2024-09-30 was $4.99M.
- PRO-DEX, INC. proceeds from issuance of long-term debt for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- PRO-DEX, INC. proceeds from issuance of long-term debt for fiscal 2023 was $5.28M, a 164.20% increase from fiscal 2022.
- PRO-DEX, INC. proceeds from issuance of long-term debt for fiscal 2022 was $2.00M, a 78.12% decline from fiscal 2021.
- PRO-DEX, INC. proceeds from issuance of long-term debt for fiscal 2021 was $9.14M.
- PRO-DEX, INC. proceeds from issuance of long-term debt for fiscal 2019 was $4.94M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-03-31 | $4.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-01 | $7.90M derived: sum of 2 quarters · filed 2025-05-01 | $12.89M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-30 | $8.49M 10-Q · filed 2025-01-30 | ||
| 2024-09-30 | $4.99M 10-Q · filed 2024-10-31 | |||
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-01 | $2.00M 10-Q · filed 2025-05-01 | ||
| 2023-12-31 | $2.00M 10-Q · filed 2025-01-30 | |||
| 2023-06-30 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-13 | $3.48M derived: sum of 2 quarters · filed 2024-05-02 | $4.28M derived: sum of 3 quarters · filed 2024-05-02 | $5.28M 10-K · filed 2023-10-13 |
| 2023-03-31 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-02 | $2.58M derived: sum of 2 quarters · filed 2024-05-02 | $3.58M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-08 | $1.80M 10-Q · filed 2024-02-08 | ||
| 2022-09-30 | $1.00M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $2.00M 10-K · filed 2023-10-13 | |||
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-13 | $3.96M derived: sum of 2 quarters · filed 2023-10-13 | $9.14M 10-K · filed 2023-10-13 | |
| 2021-03-31 | $3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-06 | $9.14M 10-Q · filed 2021-05-06 | ||
| 2020-12-31 | $5.18M 10-Q · filed 2021-02-04 | |||
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-10 | -$2.00K derived: sum of 2 quarters · filed 2020-09-10 | -$60.00K derived: sum of 3 quarters · filed 2020-09-10 | $4.94M 10-K · filed 2020-09-10 |
| 2019-03-31 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-07 | -$60.00K derived: sum of 2 quarters · filed 2020-05-07 | $4.94M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | -$58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-06 | $4.94M 10-Q · filed 2020-02-06 | ||
| 2018-09-30 | $5.00M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |